Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis
Suzuki Y et al. – Study reports that intravenous immunoglobulin therapy (IVIG) treatment is safe and could be an effective salvage therapy for refractory interstitial lung disease (ILD) associated with polymyositis/dermatomyositis (ILD-PM/DM) in certain cases, suggesting that further controlled trials are worthwhile. Methods- Aim was to investigate the efficacy of IVIG for refractory ILD-PM/DM
- Medical charts of 5 pts (2 men and 3 women) who were treated with IVIG for refractory ILD-PM/DM resistant to high-dose corticosteroid and cyclosporine A and/or cyclophosphamide were reviewed
- 1 patient had acute ILD-PM and 4 pts had acute ILD-ADM
Results- 1/5 patient with ILD-PM and 1 patient with ILD-ADM survived
- No adverse reactions were seen due to IVIG treatment
- There were no critical differences in the clinical parameters and clinical courses between survivors and nonsurvivors
[more...]
|
|
|
